Ozempic is under clinical development by Novo Nordisk and currently in Phase III for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

In recent developments, health officials in Europe have launched an investigation into the popular weight loss drug Ozempic, ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...

Novo Nordisk’s stock dives as new weight loss drug disappoints in a late-stage trial, which gave a boost to Eli Lilly shares.

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Denmark's drug regulator asks EMA to investigate potential link between Novo Nordisk's diabetes drug Ozempic and rare eye ...